Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

NCT01094769 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Nephropathies

Interventions

DRUG: Moxonidine
DRUG: Placebo

Sponsor

Baker Heart and Diabetes Institute